Department of Health - Abu Dhabi Partners with Pfizer to Advance Research in Sickle Cell Disease and Beyond

ABU DHABI, UAE, June 4, 2024 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Pfizer Gulf FZ LLC, a global pharmaceutical company during BIO 2024 International Convention. The entities will work to enhance Abu Dhabi's position as leading global hub for healthcare, life science and innovation. Leveraging the Emirate's unique capabilities and future-forward data services as well as Pfizer's global capabilities, the parties seek to advance research through the generation and analysis of real-world data (RWD) initially focusing on Sickle Cell Disease (SCD) and expanding to other disease areas for the benefit of patients.

In the presence of H.E. Mansoor Al Mansoori, Chairman of DoH, the MoU was signed by Dr Asma Al Mannaei, the Executive Director of the Research and Innovation Centre at DoH, and Serhat Yalcinkaya, Pfizer's Gulf Cluster Lead.

Dr Asma Ibrahim Al Mannaei, said: "The collaboration between the DoH and Pfizer represents a significant step towards harnessing real-world data in the region and better understanding patient populations from the vast available data in Abu Dhabi. By partnering with Pfizer on real-world data, we aim to drive advancements in healthcare prediction, prevention, personalised treatment and access, not only benefiting healthcare professionals and patients in Abu Dhabi, but also contributing to the improvement of care for patients globally."

Serhat Yalcinkaya, commented: "It is a significant moment for Pfizer Gulf as we sign this Memorandum of Understanding with the Department of Health. This collaboration is not just a testament to our shared vision but also a strategic step towards enhancing healthcare innovation in the Gulf region. Through this MoU, we are committed to leveraging Real-World Data initially focusing on Sickle Cell Disease landscape and exploring further to other disease areas, ultimately

improving patient outcomes and transforming Abu Dhabi into a global hub for life sciences. We are proud to partner with the Department of Health and look forward to the positive impact our joint efforts will bring to the communities we serve."

The two entities will work together to advance Abu Dhabi's RWD capabilities by promoting global knowledge exchange and education of scientific ideas. The agreement will focus on upskilling the local healthcare workforce on RWD by establishing a dynamic and sustainable partnership model promoting education and awareness on real-world evidence (RWE) generation, collection and analysis in order to address unmet patient needs.

About Department of Health – Abu Dhabi (DoH):

DoH is the regulatory body of the healthcare sector at the Emirate of Abu Dhabi and ensures excellence in healthcare by monitoring the health status of the population. DoH defines the strategy for the health system, monitors and analyses the health status of the population and performance of the system. In addition, DoH shapes the regulatory framework for the health system, inspects against regulations, enforce standards, and encourages adoption of world-class best practices and performance targets by all healthcare service providers in the Emirate. DoH also drives programmes to increase awareness and adoption of healthy living standards among the residents of the Emirate of Abu Dhabi in addition to regulating scope of services, premiums and reimbursement rates of the health system.

For further information on DoH, visit https://www.doh.gov.ae/

About Pfizer: 

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com

Photo - https://mma.prnewswire.com/media/2429120/DoH_Partners_with_Pfizer.jpg